glucagon-like peptide-1


Also found in: Wikipedia.

glucagon-like peptide-1

,

GLP-1

An incretin released by the gastrointestinal tract in response to consumed sugars. Analogs of GLP-1 such as exenetide and liraglutide are used to treat type 2 diabetes mellitus.
References in periodicals archive ?
Victoza, which the first glucagon-like peptide-1 (GLP-1) receptor agonist approved for children and adolescents with type 2 diabetes, provides this population with a new treatment option beyond metformin and insulin for the first time in 19 years, added the company
Novo Nordisk announced the submission of two New Drug Applications to the FDA for oral semaglutide, a once-daily glucagon-like peptide-1 analogue in a tablet, as well as a supplemental NDA for once-weekly Ozempic.
The STELLUX[R] Chemi Glucagon ELISA is highly specific with 100% cross-reactivity to glucagon, and does not cross-react with other proglucagon peptides such as oxyntomodulin, glicentin and the incretins glucagon-like peptide-1 and gastric inhibitory polypeptide.
Unlike other glucagon-like peptide-1 (GLP-1) receptor agonists, Bydureon BCise has a unique, continuous-release microsphere delivery system designed to provide consistent therapeutic levels of the active ingredient, exenatide, to help patients reach and maintain steady state.
Recently, ANP secretion was also shown to be stimulated by the incretin hormone glucagon-like peptide-1 (GLP-1) in mice (1).
This includes new medication classes as add-on therapy to metformin such as the dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists that act on the incretin system, and the sodium glucose cotransporter-2 inhibitors that act on the kidney.
Xultophy 100/3.6 enters a new class of diabetes treatments that combine a basal insulin and a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a single, once-daily injection.
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Patients taking dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) analogues were compared with those taking non-incretin-based drugs.
A tumour that secretes glucagon-like peptide-1 and somatostatin